

# Halla Thorsteinsdóttir

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4713387/publications.pdf>

Version: 2024-02-01

35  
papers

1,042  
citations

489802

18  
h-index

466096

32  
g-index

35  
all docs

35  
docs citations

35  
times ranked

1113  
citing authors

#	ARTICLE	IF	CITATIONS
1	The rise of health biotechnology research in Latin America: A scientometric analysis of health biotechnology production and impact in Argentina, Brazil, Chile, Colombia, Cuba and Mexico. PLoS ONE, 2018, 13, e0191267.	1.1	16
2	Corporate social responsibility to improve access to medicines: the case of Brazil. Globalization and Health, 2017, 13, 10.	2.4	12
3	Some factors limiting transfer of biotechnology research for health care at Cinvestav: A Mexican scientific center. Technology in Society, 2017, 48, 1-10.	4.8	2
4	Pursuing endogenous high-tech innovation in developing countries: A look at regenerative medicine innovation in Brazil, China and India. Research Policy, 2013, 42, 965-974.	3.3	41
5	Canada's Neglected Tropical Disease Research Network: Who's in the Core? Who's on the Periphery?. PLoS Neglected Tropical Diseases, 2013, 7, e2568.	1.3	14
6	Sino-Canadian Collaborations in Stem Cell Research: A Scientometric Analysis. PLoS ONE, 2013, 8, e57176.	1.1	4
7	Tackling Meningitis in Africa. Science, 2012, 338, 1546-1547.	6.0	9
8	Stakeholder involvement in expensive drug recommendation decisions: An international perspective. Health Policy, 2012, 105, 226-235.	1.4	24
9	Priority setting for orphan drugs: An international comparison. Health Policy, 2011, 100, 25-34.	1.4	39
10	Health biotechnology innovation on a global stage. Nature Reviews Microbiology, 2011, 9, 137-143.	13.6	10
11	South-South entrepreneurial collaboration in health biotech. Nature Biotechnology, 2010, 28, 407-416.	9.4	33
12	Cultivating regenerative medicine innovation in China. Regenerative Medicine, 2010, 5, 35-44.	0.8	41
13	Regenerative medicine in Brazil: small but innovative. Regenerative Medicine, 2010, 5, 863-876.	0.8	13
14	Cuba and Brazil: An Important Example of South-South Collaboration in Health Biotechnology. MEDICC Review, 2010, 12, 32.	0.5	8
15	A survey of South-North health biotech collaboration. Nature Biotechnology, 2009, 27, 229-232.	9.4	11
16	Globetrotting firms: Canada's health biotechnology collaborations with developing countries. Nature Biotechnology, 2009, 27, 806-814.	9.4	5
17	Harnessing Stem Cells for Health Needs in India. Cell Stem Cell, 2008, 3, 11-15.	5.2	20
18	The Role of the Health System in Health Biotechnology in Developing Countries. Technology Analysis and Strategic Management, 2007, 19, 659-675.	2.0	15

#	ARTICLE	IF	CITATIONS
19	Innovation Cultures in Developing Countries: The Case of Health Biotechnology. Comparative Technology Transfer and Society, 2007, 5, 178-201.	0.2	3
20	Regenerative Medicine and the Developing World. PLoS Medicine, 2006, 3, e381.	3.9	63
21	Biotechnology patenting takes off in developing countries. International Journal of Biotechnology, 2006, 8, 43.	1.2	22
22	Enabling knowledge societies in developing countries: the example of genomics. International Journal of Biotechnology, 2006, 8, 4.	1.2	1
23	Health biotechnology publishing takes-off in developing countries. International Journal of Biotechnology, 2006, 8, 23.	1.2	17
24	Regenerative medicine: new opportunities for developing countries. International Journal of Biotechnology, 2006, 8, 60.	1.2	45
25	Strengthening the Role of Genomics in Global Health. PLoS Medicine, 2004, 1, e40.	3.9	18
26	Health biotechnology in China—reawakening of a giant. Nature Biotechnology, 2004, 22, DC13-DC18.	9.4	21
27	Cuba—innovation through synergy. Nature Biotechnology, 2004, 22, DC19-DC24.	9.4	42
28	Introduction: promoting global health through biotechnology. Nature Biotechnology, 2004, 22, DC3-DC7.	9.4	25
29	Indian biotechnology—rapidly evolving and industry led. Nature Biotechnology, 2004, 22, DC31-DC36.	9.4	41
30	South Africa—blazing a trail for African biotechnology. Nature Biotechnology, 2004, 22, DC37-DC41.	9.4	23
31	Conclusions: promoting biotechnology innovation in developing countries. Nature Biotechnology, 2004, 22, DC48-DC52.	9.4	52
32	Genomics knowledge and equity: a global public goods perspective of the patent system. Bulletin of the World Health Organization, 2004, 82, 385-9.	1.5	14
33	Genomics—a global public good?. Lancet, The, 2003, 361, 891-892.	6.3	21
34	Top ten biotechnologies for improving health in developing countries. Nature Genetics, 2002, 32, 229-232.	9.4	304
35	Public-sector research in small countries: does size matter?. Science and Public Policy, 2000, 27, 433-442.	1.2	13